COMMUNIQUÉS West-GlobeNewswire

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
12/12/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 DECEMBER 2024 at 20.30 EET Penalty payment to a member of Orion’s Board of Directors for delay in [...]
FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research
12/12/2024
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024 , held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements [...]
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
12/12/2024
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for [...]
EssilorLuxottica: EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi)
12/12/2024
EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi) Paris, France (12 December 2024) – EssilorLuxottica announced today that its near-term greenhouse [...]
EssilorLuxottica: Les objectifs à court terme de réduction des émissions de gaz à effet de serre d'EssilorLuxottica ont été validés par l’initiative Science Based Target (SBTi)
12/12/2024
Les objectifs à court terme de réduction des émissions de gaz à effet de serre d'EssilorLuxottica ont été validés par l’initiative Science Based Target (SBTi) Paris, France (12 décembre 2024) – EssilorLuxottica a [...]
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
12/12/2024
Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings [...]
ACARIZAX® approved in Europe for treatment of young children
12/12/2024
ALK ( ALKB:DC / OMX: ALK B ) today announced that its European regulatory filing for ACARIZAX ® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health [...]
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors
12/12/2024
Dr. Doberstein brings extensive biotech leadership experience as the company advances its AI-powered pipeline into Phase 2 for immune-mediated inflammatory disorders GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- [...]
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
12/12/2024
MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
XORTX Announces Presentation at the Rare and Genetic Disease Summit
12/12/2024
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12/12/2024
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032 [...]
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12/12/2024
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE [...]
HWH International Inc. announces plans to expand its Robotics division into the U.S. by establishing a Dallas, Texas based showroom and starting its marketing efforts in the 1st quarter of 2025.
12/12/2024
BETHESDA, MD, Dec. 12, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) is proud to announce its plans to begin its marketing efforts in the U.S. in the first quarter of 2025. The Company’s wholly [...]
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
12/12/2024
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose ( [...]
Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
12/12/2024
Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the [...]
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
12/12/2024
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare [...]
Revolo Announces New Preclinical Data Supporting Subcutaneous ‘1104 for Atopic Dermatitis and Other Clinical Programs
12/12/2024
In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models evaluated in single-dose [...]
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
12/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products [...]
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
12/12/2024
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a novel trispecific T cell engager, as fifth [...]

Pages